Biotech buyouts. Does Roche's pretty aggressive $3.4 billion swallowing of Ventana qualify for your table? It was finally consummated in Feb 2008 and represented a hefty 73% premium to the share price prior to their first hostile offer last year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.